ArticleBritish journal of cancer2024

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.

Maryam Arshad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.